Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027

LONDON, November 1, 2017 /PRNewswire/ --

 - Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs

Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

Discover how to stay ahead: 

Our 139-page report provides 96 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Checkpoint Inhibitors for Treating Cancer market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects: 

• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets: 

Along with revenue prediction for the overall world market, there are forecasts for 3 submarkets and 7 Drugs in the report at a global level, as well as profiles for 19 pipeline drug candidates

Global Checkpoint Inhibitors for Treating Cancer Market by Type: 

• PD-1 Inhibitors
• CLTA-4 Inhibitors
• Pipeline Drugs 

Global Checkpoint Inhibitors for Treating Cancer Market by Drug: 

• Opdivo (nivolumab)
• Keytruda (pembrolizumab)
• Yervoy (ipilimumab)
• Tecentriq (Atezolizumab)
• Imfinizi (Durvalumab)
• Bavencio - Avelumab - (MSB0010718C)
• Tremelimumab (CP-675,206) 

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 8 major regional/national markets:

• The US
• Japan
• Germany
• The UK
• Italy
• France
• Spain
• Asia-Pacific

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth: 

Overall world revenue for Checkpoint Inhibitors for Treating Cancer will surpass $7.6bn in 2017, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market report helps you: 

In summary, our 139-page report provides you with the following knowledge:

• Revenue forecasts to 2027 for the Checkpoint Inhibitors for Treating Cancer market, with forecasts for 3 submarkets and 7 Drugs, each forecasted at a global level - discover the industry's prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2027 for 8 key regional and national markets - See forecasts for the Checkpoint Inhibitors for Treating Cancer in Asia-Pacific, the US, Germany, France, the UK, Italy, France, and Japan,

• What stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market - including company profiles for some of the major companies involved in the Checkpoint Inhibitors for Treating Cancer market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else: 

With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain's study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer market and leading companies. You will find data, trends and predictions.

Get our report today Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com (+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/Report/2034/Checkpoint-Inhibitors-for-Treating-Cancer-Market-Report-2017-2027

Companies Mentioned in the Report 

AbbVie

Agilent Technologies

Amgen

Amplimmune

AnaptysBio

AstraZeneca

Aurigene Discovery Technologies

Bristol-Myers Squibb

Celgene

CoStim Pharmaceuticals

CureTech Ltd

Curis Inc

Daiichi Sankyo

Dako (subsidiary of Agilent Technologies)

DMC (Data Monitoring Committee)

DNAtrix

Dynavax

Eddingpharm

GlaxoSmithKline (GSK)

Heptares

Immutep

Incyte

Innate Pharma

INSERM

iTeos Therapeutics

J&J

Medarex

MedImmune

Medivation Inc

Merck & Co.

Merck KGaA

Mirati Therapeutics

NEC Corporation

NewLink Genetics

Novartis

Novo Nordisk

Ono Pharmaceutical

Pfizer

Pharmacyclics

Plexxikon (subsidiary of Daiichi Sankyo)

Prima Biomed

Regeneron

Roche

Sanofi

Sosei Group Corporation

Syndax

TESARO Inc

Teva Pharmaceutical Industries

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com, +44(0)20-73366100